NexgenRx reports Q3 results
- NexgenRx press release (NXG:CA): Q3 EBITDA of $1,048,210, representing significant percentage increases of 8%, 48.8% and 18.1%, respectively, compared to the same period in 2025.
- Revenue of $4.9M.
- The company recorded a net loss of $63.99K compared to net income of $589.78K in the same period last year.
More on NexgenRx
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.